Joana Carvalho, PhD, managing science editor —

Treatment with Nuplazid (pimavanserin) significantly delays time to a psychosis relapse in people with dementia-related disorders such as Alzheimer’s and Parkinson’s diseases, according to results from the ongoing Phase 3 HARMONY study. Evaluation by an independent data monitoring committee recommended an early stop to this trial based on the…

PTI-125, Cassava Sciences’ lead therapeutic candidate for the treatment of Alzheimer’s disease, significantly reduced the levels of disease biomarkers, brain inflammation, and neurodegeneration after 28 days of treatment, top-line data from a Phase 2 trial show. “Based on these encouraging biomarker results, this new treatment could be…

Scientists have found a series of brain alterations associated with Alzheimer’s disease that occur decades before the onset of the first symptoms. Identifying these biological and anatomical brain alterations in people at high-risk for the disease may help them receive earlier therapeutic interventions, the researchers said. The study, “…

The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded $1.5 million to Oryzon Genomics to support expanding an ongoing Phase 2a trial assessing the potential of vafidemstat (ORY-2001) in patients with mild to moderate Alzheimer’s disease to the United States. The double-blind, placebo-controlled trial (2017-004893-32), called…

High blood levels of primary fatty acid amides (PFAMS), a class of fatty molecules involved in sleep and movement control, are associated with increased accumulation of beta-amyloid protein in the cerebrospinal fluid of patients with Alzheimer’s disease, a study finds. Researchers believe that this class of fatty…

Latest findings from the open-label extension (OLE) Phase 3 clinical trials Scarlet RoAD (NCT01224106) and Marguerite RoAD (NCT02051608) on gantenerumab (RG1450, RO4909832) continue to show significant reductions in the accumulation of amyloid plaques in patients with Alzheimer’s disease with and without amyloid-related imaging abnormalities-edema (ARIA-E).

The combination of two factors, aging and eating foods high in sugar or fats, raises susceptibility to Alzheimer’s disease, a study in mice reports. The research, “Evaluation of neuropathological effects of a high‐fat high‐sucrose diet in middle‐aged male C57BL6/J mice,” was published in Physiological Reports. Alzheimer’s disease is a…